Contact

Beta Amyloid A4 Peptides for Alzheimer's Disease Research

The A beta peptide (synonyms are Beta Amyloid peptide or Abeta peptide) is the main component of amyloid peptide plaques in the brain of patients with Alzheimer's disease. JPT provides a broad selection of chemically synthesized amyloid beta peptides for Alzheimer's disease research. We supply A beta peptides of different lengths and point-mutated versions of A beta (1-42) which are known to be related to the familial forms of Alzheimer's disease. They are provided as HFIP-films (HFIP = hexafluoroisopropanol) which removes any unwanted secondary peptide structure and pre-existing oligomeric/polymeric forms.

Available Amyloid beta A4 peptides

SP-Ab-12_0.1A21G-Beta-Amyloid (1-42); HFIP treated (0.1mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 protein (natural variant)Info
SP-Ab-12_0.5A21G-Beta-Amyloid (1-42); HFIP treated (0.5mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 protein (natural variant)Info
SP-Ab-28_0.1A2T-Beta-Amyloid (1-40); HFIP treated (0.1mg) Variant of human A beta (Amyloid beta) protein, where Ala 2 is replaced by a Threonine (Thr)Info
SP-Ab-28_0.5A2T-Beta-Amyloid (1-40); HFIP treated (0.5mg) Variant of human A beta (Amyloid beta) protein, where Ala 2 is replaced by a Threonine (Thr)Info
SP-Ab-25_0.1A2T-Beta-Amyloid (1-42); HFIP treated (0.1mg) Variant of human Amyloid beta A4 protein, where Ala 2 is replaced by a Threonine (Thr)Info
SP-Ab-25_0.5A2T-Beta-Amyloid (1-42); HFIP treated (0.5mg) Variant of human Amyloid beta A4 protein, where Ala 2 is replaced by a Threonine (Thr)Info
SP-Ab-27_0.1A2V-Beta-Amyloid (1-40); HFIP treated (0.1mg) Variant of human A beta (Amyloid beta) protein, where Ala 2 is replaced by a Valine (Val)Info
SP-Ab-27_0.5A2V-Beta-Amyloid (1-40); HFIP treated (0.5mg) Variant of human A beta (Amyloid beta) protein, where Ala 2 is replaced by a Valine (Val)Info
SP-Ab-26_0.1A2V-Beta-Amyloid (1-42); HFIP treated (0.1mg) Variant of human Amyloid beta A4 protein, where Ala 2 is replaced by a Valine (Val)Info
SP-Ab-26_0.5A2V-Beta-Amyloid (1-42); HFIP treated (0.5mg) Variant of human Amyloid beta A4 protein, where Ala 2 is replaced by a Valine (Val)Info
SP-Ab-20_0.1Beta-Amyloid (1-37); HFIP treated (0.1mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-20_0.5Beta-Amyloid (1-37); HFIP treated (0.5mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-21_0.1Beta-Amyloid (1-38); HFIP treated (0.1mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-21_0.5Beta-Amyloid (1-38); HFIP treated (0.5mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-18_0.1Beta-Amyloid (1-40)-Lys(Biotinoyl); HFIP (0.1mg) Synthetic C-terminally biotinylated peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-18_0.5Beta-Amyloid (1-40)-Lys(Biotinoyl); HFIP (0.5mg) Synthetic C-terminally biotinylated peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-06_0.1Beta-Amyloid (1-40); HFIP treated (0.1mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-06_0.5Beta-Amyloid (1-40); HFIP treated (0.5mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-16_0.1Beta-Amyloid (1-42)-Lys(Biotinoyl); HFIP treated (0.1mg) Synthetic C-terminally biotinylated peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-16_0.5Beta-Amyloid (1-42)-Lys(Biotinoyl); HFIP treated (0.5mg) Synthetic C-terminally biotinylated peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-07_0.1Beta-Amyloid (1-42); HFIP treated (0.1mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-07_0.5Beta-Amyloid (1-42); HFIP treated (0.5mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-08_0.1Beta-Amyloid (1-43); HFIP treated (0.1mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-08_0.5Beta-Amyloid (1-43); HFIP treated (0.5mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-22_0.1Beta-Amyloid (17-40); HFIP treated (0.1mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-22_0.5Beta-Amyloid (17-40); HFIP treated (0.5mg) A-peptide variants of Homo sapiens (Human) Info
SP-Ab-23_0.1Beta-Amyloid (17-42); HFIP treated (0.1mg) A-peptide variants of Homo sapiens (Human) Info
SP-Ab-23_0.5Beta-Amyloid (17-42); HFIP treated (0.5mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-19_0.1Biotinoyl-Beta-Amyloid (1-40); HFIP treated (0.1mg) Synthetic N-terminally biotinylated peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-19_0.5Biotinoyl-Beta-Amyloid (1-40); HFIP treated (0.5mg) Synthetic N-terminally biotinylated peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-17_0.1Biotinoyl-Beta-Amyloid (1-42); HFIP treated (0.1mg) Synthetic N-terminally biotinylated peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-17_0.5Biotinoyl-Beta-Amyloid (1-42); HFIP treated (0.5mg) Synthetic N-terminally biotinylated peptide derived from the N-terminal region of human Amyloid beta A4 proteinInfo
SP-Ab-15_0.1D23N-Beta-Amyloid (1-42); HFIP treated (0.1mg) Iowa variant of human Amyloid beta A4 protein, where Asp 23 is replaced by an Asparagine (Asn)Info
SP-Ab-15_0.5D23N-Beta-Amyloid (1-42); HFIP treated (0.5mg) Iowa variant of human Amyloid beta A4 protein, where Asp 23 is replaced by an Asparagine (Asn)Info
SP-Ab-09_0.1D7N-Beta-Amyloid (1-42); HFIP treated (0.1mg) Tottori-Japanese variant of human Amyloid beta A4 protein, where Asp 7 is replaced by an Asparagine (Asn)Info
SP-Ab-09_0.5D7N-Beta-Amyloid (1-42); HFIP treated (0.5mg) Tottori-Japanese variant of human Amyloid beta A4 protein, where Asp 7 is replaced by an Asparagine (Asn)Info
SP-Ab-10_0.1E11K-Beta-Amyloid (1-42); HFIP treated (0.1mg) Variant of human Amyloid beta A4 protein, where Glu 11 is replaced by a Lysine (Lys)Info
SP-Ab-10_0.5E11K-Beta-Amyloid (1-42); HFIP treated (0.5mg) Variant of human Amyloid beta A4 protein, where Glu 11 is replaced by a Lysine (Lys)Info
SP-Ab-11_0.1E22G-Beta-Amyloid (1-42); HFIP treated (0.1mg) Arctic variant of human Amyloid beta A4 protein, where Glu 22 is replaced by a Glycine (Gly)Info
SP-Ab-11_0.5E22G-Beta-Amyloid (1-42); HFIP treated (0.5mg) Arctic variant of human Amyloid beta A4 protein, where Glu 22 is replaced by a Glycine (Gly)Info
SP-Ab-13_0.1E22K-Beta-Amyloid (1-42); HFIP treated (0.1mg) Italian variant of human Amyloid beta A4 protein, where Glu 22 is replaced by a Lysine (Lys)Info
SP-Ab-13_0.5E22K-Beta-Amyloid (1-42); HFIP treated (0.5mg) Italian variant of human Amyloid beta A4 protein, where Glu 22 is replaced by a Lysine (Lys)Info
SP-Ab-14_0.1E22Q-Beta-Amyloid (1-42); HFIP treated (0.1mg) Dutch variant of human Amyloid beta A4 protein, where Glu 22 is replaced by a Glutamine (Gln)Info
SP-Ab-14_0.5E22Q-Beta-Amyloid (1-42); HFIP treated (0.5mg) Dutch variant of human Amyloid beta A4 protein, where Glu 22 is replaced by a Glutamine (Gln)Info
SP-Ab-29_0.1pyrGlu Beta-Amyloid (3-40); HFIP treated (0.1mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 protein (variant)Info
SP-Ab-29_0.5pyrGlu Beta-Amyloid (3-40); HFIP treated (0.5mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 protein (variant)Info
SP-Ab-30_0.1pyrGlu³ Beta-Amyloid (3-42); HFIP treated (0.1mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 protein (variant) for Alzheimer research Info
SP-Ab-30_0.5pyrGlu³ Beta-Amyloid (3-42); HFIP treated (0.5mg) Synthetic peptide derived from the N-terminal region of human Amyloid beta A4 protein (variant) for Alzheimer research Info
SP-Ab-24_0.1S26C-Beta-Amyloid (1-40) Dimer; HFIP treated (0.1mg) Homodimer of human Amyloid beta A4 peptide (1-40), where Ser 26 is replaced by an Cysteine (Cys) that is used for dimerizationInfo
SP-Ab-24_0.5S26C-Beta-Amyloid (1-40) Dimer; HFIP treated (0.5mg) Homodimer of human Amyloid beta A4 peptide (1-40), where Ser 26 is replaced by an Cysteine (Cys) that is used for dimerizationInfo

Applications of JPT's Amyloid beta peptides (A beta, Beta Amyloid)

  • In vitro staining
  • Protein-protein interaction studies
  • Western Blot
  • Binding experiments

Application Note:
"Synthetic Amyloid Beta Peptides Aid Alzheimer Investigation"
by A. Vandersteen et al.

Benefits of JPT's Amyloid beta peptides (A beta, Beta Amyloid)

  • All amyloid-ß peptides are well characterized and provided as HFIP-films. This guarantees that all samples contain the same chemically and structurally homogenous material without any unwanted secondary structures
  • Production is performed in our German facilities and is ISO 9001:2015 & GCLP certified
  • Greatest variety of Abeta sequence modifications in stock - available within days!
  • Not found what you are looking for? Request a quote for custom peptide synthesis to obtain your tailored A beta peptide

Testimonial for JPT's Amyloid beta peptides (A beta, Beta Amyloid)

"Our group focuses on the in vitro study of risk factors in Alzheimer’s disease and, as we experienced that the in-house expression and production of the amyloid beta peptide is notoriously difficult, we are continuously dependent on a high quality supply of a large variety of these peptides from commercial source.  We started our collaboration with JPT with their request to test a range of their peptides for the ability to produce toxic oligomers and fibrillar networks and were impressed by the rapid supply of a very wide range of high purity peptides with excellent fibril forming properties and toxicity profiles. JPT has shown real valuable know-how and experience in the field of peptide synthesis by their ability to generate high quality preparations of amyloid beta peptide variants which are known for their difficulty to handle.”
Kerensa Broersen, Assistant Prof., Nanobiophysics Group, University of Twente, Enschede, The Netherlands

More testimonials

News Highlights

JPT's A Beta Peptides Pass the Test!
Read the latest Application Note: 
Synthetic Amyloid Beta Peptides 
Aid Alzheimer Investigation

by Kerensa Broersen, 
University of Twente, Enschede
(March 2013)

Quality Assurance

All production is performed according to ISO 9001:2015 standards

Stay in touch and be the first to receive the latest news!